



wherein R₁ is halogen or R'₁-X wherein X = NH, O, S, S(O₂).

R'₁ is alkyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, and alkynyl, each having one to 20 carbon atoms, which alkyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, and alkynyl, are optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, aryl, CF₃, heteroaryl, heterocyclyl, R²², SR²⁰, S(O)R²¹, SO₂R²¹, SO₂NR²⁰R²³, SO₂NR²⁰COR²¹, SO₂NR²⁰CONR²⁰R²³, SO₂NR²⁰CO₂R²¹, NR²⁰R²³, NR²⁰COR²¹, NR²⁰CO₂R²¹, NR²⁰CONR²⁰R²³, N(R²⁰)C(NR²⁰)NHR²³, NR²⁰SO₂R²¹, OR²⁰, OCONR²⁰R²³, OCONR²⁰SO₂R²¹, OCONR²⁰R²³, CN, CO₂R²⁰, CONR²⁰R²³, CONR²⁰SO₂R²¹ and COR²⁰;

R₂ is a hydrogen or hydrocarbon selected from the group alkyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, and alkynyl, each having one to 20 carbon atoms, which alkyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, and alkynyl, are optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, aryl, heteroaryl, heterocyclyl, R²², SR²⁰, S(O)R²¹, SO₂R²¹, SO₂NR²⁰R²³, SO₂NR²⁰COR²¹, SO₂NR²⁰CONR²⁰R²³, SO₂NR²⁰CO₂R²¹, NR²⁰R²³, NR²⁰COR²¹, NR²⁰CO₂R²¹, NR²⁰CONR²⁰R²³, N(R²⁰)C(NR²⁰)NHR²³, NR²⁰SO₂R²¹, OR²⁰,

OCOR²⁰R²³, OCONR²⁰SO₂R²¹, OCONR²⁰R²³, CN, CO₂R²⁰, CONR²⁰R²³,
CONR²⁰SO₂R²¹ and COR²⁰;

B³
cont
A1
R₃ is -NR₄R₅, wherein R₄ and R₅ are each independently hydrogen, or a hydrocarbon selected from the group including alkyl, acyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, and alkynyl, each having one to 20 carbon atoms, which alkyl, acyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, and alkynyl, are optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, aryl, heteroaryl, heterocyclyl, R²², SR²⁰, S(O)R²¹, SO₂R²¹, SO₂NR²⁰R²³, SO₂NR²⁰COR²¹, SO₂NR²⁰CONR²⁰R²³, SO₂NR²⁰CO₂R²¹, NR²⁰R²³, NR²⁰COR²¹, NR²⁰CO₂R²¹, NR²⁰CONR²⁰R²³, N(R²⁰)C(NR²⁰)NHR²³, NR²⁰SO₂R²¹, OR²⁰, OCONR²⁰R²³, OCONR²⁰SO₂R²¹, OCONR²⁰R²³, CN, CO₂R²⁰, CONR²⁰R²³, CONR²⁰SO₂R²¹ and COR²⁰, with the proviso that either R₄ or R₅ must be substituted with NR₂₀R₂₃]

and wherein when R₃ is 2-hydroxyethylamino and R₂ is methyl then R₁'-X is not amino, 3-methyl-2-butenylamino, benzylamino, or m-hydroxybenzylamino]

OK
9L
wherein when R₃ is not 2-hydroxyethylamino and R₂ is isopropyl, then R₁'-X is not benzylamino, m-hydroxybenzylamino, or 3-methylbutylamino] and wherein when R₃ is 2-hydroxyethylamino and R₂ is 2-hydroxyethyl, then R₁'-X is not benzylamino]

5012
wherein when R₃ is selected from the group consisting of 2-methyl-2-hydroxypropylamino and 2-dimethylaminoethylamino, and when R₂ is methyl, then R₁'-X is not benzylamino]

R²⁰ is a member selected from the group consisting of H, C₁₋₁₅ alkyl, C₂₋₁₅ alkenyl, C₂₋₁₅ alkynyl, heterocyclyl, aryl, and heteroaryl, which alkyl, alkenyl, alkynyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with 1 to 3 substituents

independently selected from halo, alkyl, mono- or dialkylamino, alkyl or aryl or heteroaryl amide, CN, O-C₁₋₆ alkyl, CF₃, aryl, and heteroaryl;

R^{21} is a member selected from the group consisting of C₁₋₁₅ alkyl, C₂₋₁₅ alkenyl, C₂₋₁₅ alkynyl, heterocyclyl, aryl, and heteroaryl, which alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and heteroaryl are optionally substituted with 1 to 3 substituents independently selected from the group of halo, heterocyclyl, aryl, heteroaryl, CF₃, CN, OR²⁰, SR²⁰, N(R²⁰)₂, S(O)R²², SO₂R²², SO₂N(R²⁰)₂, SO₂NR²⁰COR²², SO₂NR²⁰CO₂R²², SO₂NR²⁰CON(R²⁰)₂, N(R²⁰)₂NR²⁰COR²², NR²⁰CO₂R²², NR²⁰CON(R²⁰)₂, NR²⁰C(NR²⁰)NHR²³, COR²⁰, CO₂R²⁰, CON(R²⁰)₂, CONR²⁰SO₂R²², NR²⁰SO₂R²², SO₂NR²⁰CO₂R²², OR²⁰, OCONR²⁰SO₂R²², OC(O)R²⁰, C(O)OCH₂OC(O)R²⁰, and OCON(R²⁰)₂, and each optional heteroaryl, aryl, and heterocyclyl substituent is optionally substituted with halo, alkyl, CF₃, amino, mono- or di-alkylamino, alkyl or aryl or heteroaryl amide, NCOR²², NR²⁰SO₂R²², COR²⁰, CO₂R²⁰, CON(R²⁰)₂, NR²⁰CON(R²⁰)₂, OC(O)R²⁰, OC(O)N(R²⁰)₂, SR²⁰, S(O)R²², SO₂R²², SO₂N(R²⁰)₂, CN, or OR²⁰;

R^{22} is a member selected from the group consisting of C₁₋₁₅ alkyl, C₂₋₁₅ alkenyl, C₂₋₁₅ alkynyl, heterocyclyl, aryl, and heteroaryl, which alkyl, alkenyl, alkynyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with 1 to 3 substituents independently selected from halo, alkyl, mono- or dialkylamino, alkyl or aryl or heteroaryl amide, CN, O-C₁₋₆ alkyl, CF₃, aryl, and heteroaryl; and

R^{23} is R^{21} or H.

51. (New) A 2,6,9-trisubstituted purine composition of claim 50 wherein:

09929772-081401

AI

R_1 is a alkyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, and alkynyl, each having one to 20 carbon atoms, which alkyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, and alkynyl, are optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, CF_3 , aryl, heteroaryl, heterocyclyl, R^{22} , SR^{20} , $S(O)R^{21}$, SO_2R^{21} , $SO_2NR^{20}R^{23}$, $NR^{20}R^{23}$, $NR^{20}COR^{21}$, $NR^{20}CO_2R^{21}$, $NR^{20}CONR^{20}R^{23}$, $NR^{20}SO_2R^{21}$, OR^{20} , CN, CO_2R^{20} , $CONR^{20}R^{23}$, and COR^{20} .

R_2 is a hydrogen or hydrocarbon selected from the group substituted-alkyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, and alkynyl, each having one to 20 carbon atoms, which alkyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, and alkynyl, are optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, aryl, heteroaryl, heterocyclyl, R^{22} , SR^{20} , $S(O)R^{21}$, SO_2R^{21} , $SO_2NR^{20}R^{23}$, $NR^{20}R^{23}$, $NR^{20}COR^{21}$, $NR^{20}CO_2R^{21}$, $NR^{20}CONR^{20}R^{23}$, $NR^{20}SO_2R^{21}$, OR^{20} , CN, CO_2R^{20} , $CONR^{20}R^{23}$, and COR^{20} .

R_4 and R_5 are each independently hydrogen, or a hydrocarbon selected from the group including alkyl, acyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, and alkynyl, each having one to 20 carbon atoms, which alkyl, acyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, and alkynyl, are optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, aryl, heteroaryl, heterocyclyl, R^{22} , SR^{20} , $S(O)R^{21}$, SO_2R^{21} , $SO_2NR^{20}R^{23}$, $NR^{20}R^{23}$, $NR^{20}COR^{21}$, $NR^{20}CO_2R^{21}$, $NR^{20}CONR^{20}R^{23}$, $NR^{20}SO_2R^{21}$, OR^{20} , CN, CO_2R^{20} ,

CONR²⁰R²³, and COR²⁰ with the proviso that either R₄ or R₅ must be substituted with NR₂₀R₂₃;

A1
R²⁰ is a member selected from the group consisting of H, C₁₋₈alkyl, C₂₋₈ alkenyl, C₂₋₁₅ heterocyclyl, aryl, and heteroaryl, which alkyl, alkenyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with 1 to 3 substituents independently selected from halo, alkyl, mono- or dialkylamino, alkyl or aryl or heteroaryl amide, CN, O-C₁₋₆ alkyl, CF₃, aryl, and heteroaryl;

R²¹ is a member selected from the group consisting of C₁₋₈ alkyl, C₂₋₈ alkenyl, heterocyclyl, aryl, and heteroaryl, which alkyl, alkenyl, aryl, heterocyclyl, and heteroaryl are optionally substituted with 1 to 3 substituents independently selected from the group of halo, heterocyclyl, aryl, heteroaryl, CF₃, CN, OR²⁰, SR²⁰, N(R²⁰)₂, S(O)R²², SO₂R²², SO₂N(R²⁰)₂, SO₂NR²⁰COR²², SO₂NR²⁰CO₂R²², SO₂NR²⁰CON(R²⁰)₂, N(R²⁰)₂NR²⁰COR²², NR²⁰CO₂R²², NR²⁰CON(R²⁰)₂, NR²⁰C(NR²⁰)NHR²³, COR²⁰, CO₂R²⁰, CON(R²⁰)₂, CONR²⁰SO₂R²², NR²⁰SO₂R²², SO₂NR²⁰CO₂R²², OR²⁰, OCONR²⁰SO₂R²², OC(O)R²⁰, C(O)OCH₂OC(O)R²⁰, and OCON(R²⁰)₂, and each optional heteroaryl, aryl, and heterocyclyl substituent is optionally substituted with halo, alkyl, CF₃, amino, mono- or di-alkylamino, alkyl or aryl or heteroaryl amide, NCOR²², NR²⁰SO₂R²², COR²⁰, CO₂R²⁰, CON(R²⁰)₂, NR²⁰CON(R²⁰)₂, OC(O)R²⁰, OC(O)N(R²⁰)₂, SR²⁰, S(O)R²², SO₂R²², SO₂N(R²⁰)₂, CN, or OR²⁰; and

R²² is a member selected from the group consisting of C₁₋₈ alkyl, C₂₋₈alkenyl, heterocyclyl, aryl, and heteroaryl, which alkyl, alkenyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with 1 to 3 substituents independently selected from halo, alkyl,

mono- or dialkylamino, alkyl or aryl or heteroaryl amide, CN, O-C₁₋₆ alkyl, CF₃, aryl, and heteroaryl.

52. (New) A 2,6,9-trisubstituted purine composition of claim 50 wherein:

push B4 A1

R'₁ is alkyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, and alkynyl, each having one to 20 carbon atoms, which alkyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, and alkynyl, are optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, CF₃, aryl, heteroaryl, heterocyclyl, R²², SR²⁰, S(O)R²¹, SO₂R²¹, SO₂NR²⁰R²³, NR²⁰R²³, NR²⁰COR²¹, NR²⁰CO₂R²¹, NR²⁰SO₂R²¹, OR²⁰, CN, CO₂R²⁰, CONR²⁰R²³, and COR²⁰;

R₂ is a hydrogen or hydrocarbon selected from the group including alkyl, heterocyclyl, and aryl, each having one to 10 carbon atoms, which alkyl, heterocyclyl, aryl, are optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, aryl, heteroaryl, heterocyclyl, R²², SR²⁰, S(O)R²¹, SO₂R²¹, SO₂NR²⁰R²³, NR²⁰R²³, NR²⁰COR²¹, NR²⁰CO₂R²¹, NR²⁰SO₂R²¹, OR²⁰, CN, CO₂R²⁰, CONR²⁰R²³, and COR²⁰;

R₄ and R₅ are each independently hydrogen, or a hydrocarbon selected from the group including alkyl, acyl, heterocyclyl, aryl, heteroaryl, aralkyl, alkenyl, and alkynyl, each having one to 20 carbon atoms, which alkyl, acyl, heterocyclyl, aryl, heteroaryl, aralkyl, alkenyl, and alkynyl, are optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, aryl, heteroaryl, heterocyclyl, R²², SR²⁰, S(O)R²¹, SO₂R²¹, SO₂NR²⁰R²³, NR²⁰R²³, NR²⁰COR²¹, NR²⁰CO₂R²¹, NR²⁰SO₂R²¹, OR²⁰, CN, CO₂R²⁰, CONR²⁰R²³, and COR²⁰ with the proviso that either R₄ or R₅ must be substituted with NR₂₀R₂₃;

B4
cont

R^{20} is a member selected from the group consisting of H, C_{1-8} alkyl, aryl, and heteroaryl, which alkyl, aryl, and heteroaryl are optionally substituted with 1 to 3 substituents independently selected from halo, alkyl, mono- or dialkylamino, alkyl or aryl or heteroaryl amide, CN, O- C_{1-6} alkyl, CF_3 ;

A1

R^{21} is a member selected from the group consisting of C_{1-8} alkyl, aryl, and heteroaryl, which alkyl, aryl, and heteroaryl are optionally substituted with 1 to 2 substituents independently selected from the group of halo, CF_3 , CN, OR^{20} , SR^{20} , $N(R^{20})_2$, $S(O)R^{22}$, SO_2R^{22} , $SO_2N(R^{20})_2$, $NR^{20}CO_2R^{22}$, $NR^{20}CON(R^{20})_2$, COR^{20} , CO_2R^{20} , $CON(R^{20})_2$, $NR^{20}SO_2R^{22}$, OR^{20} ; and

R^{22} is a member selected from the group consisting of C_{1-8} alkyl, aryl, and heteroaryl, which alkyl, aryl, and heteroaryl are optionally substituted with 1 to 3 substituents independently selected from halo, alkyl, mono- or dialkylamino, alkyl or aryl or heteroaryl amide, CN, O- C_{1-6} alkyl, CF_3 , aryl, and heteroaryl.

53. (New) A 2,6,9-trisubstituted purine composition of claim 50 wherein:

R'_1 is a alkyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, and alkynyl, each having one to 20 carbon atoms, which alkyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, alkenyl, and alkynyl, are optionally with from 1 to 2 substituents independently selected from the group consisting of halo, CF_3 , aryl, R^{22} , SR^{20} , $S(O)R^{21}$, SO_2R^{21} , $SO_2NR^{20}R^{23}$, $NR^{20}R^{23}$, $NR^{20}COR^{21}$, $NR^{20}CO_2R^{21}$, $NR^{20}SO_2R^{21}$, OR^{20} , CN, CO_2R^{20} , and $CONR^{20}R^{23}$;

R_2 is a hydrogen or hydrocarbon selected from the group alkyl, heterocyclyl, and aryl, each having one to 10 carbon atoms, which alkyl, heterocyclyl, aryl, are optionally substituted with from 1 to 2 substituents independently selected from the group consisting

of halo, aryl, heteroaryl, heterocyclyl, R^{22} , SR^{20} , $S(O)R^{21}$, SO_2R^{21} , $SO_2NR^{20}R^{23}$, $NR^{20}R^{23}$, $NR^{20}COR^{21}$, $NR^{20}CO_2R^{21}$, $NR^{20}SO_2R^{21}$, OR^{20} , CN , CO_2R^{20} , $CONR^{20}R^{23}$, and COR^{20} ;

R_4 and R_5 are each independently hydrogen, or a hydrocarbon selected from the group including alkyl, acyl, heterocyclyl, aryl, heteroaryl, aralkyl, alkenyl, and alkynyl, each having one to 20 carbon atoms, which alkyl, acyl, heterocyclyl, aryl, heteroaryl, aralkyl, alkenyl, and alkynyl, are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, aryl, R^{22} , SR^{20} , $S(O)R^{21}$, SO_2R^{21} , $SO_2NR^{20}R^{23}$, $NR^{20}R^{23}$, $NR^{20}COR^{21}$, $NR^{20}CO_2R^{21}$, $NR^{20}SO_2R^{21}$, OR^{20} , CN , CO_2R^{20} , and $CONR^{20}R^{23}$ with the proviso that either R_4 or R_5 must be substituted with $NR^{20}R^{23}$;

R^{20} is a member selected from the group consisting of H, C_{1-8} alkyl, aryl, and heteroaryl, which alkyl, aryl, and heteroaryl are optionally substituted with 1 to 3 substituents independently selected from halo, alkyl, mono- or dialkylamino, alkyl or aryl or heteroaryl amide, CN , $O-C_{1-6}$ alkyl, CF_3 ;

R^{21} is a member selected from the group consisting of C_{1-8} alkyl, aryl, and heteroaryl, which alkyl, aryl, and heteroaryl are optionally substituted with 1 to 2 substituents independently selected from the group of halo, CF_3 , CN , OR^{20} , SR^{20} , $N(R^{20})_2$, $S(O)R^{22}$, SO_2R^{22} , $SO_2N(R^{20})_2$, $NR^{20}CO_2R^{22}$, $NR^{20}CON(R^{20})_2$, COR^{20} , CO_2R^{20} , $CON(R^{20})_2$, $NR^{20}SO_2R^{22}$, OR^{20} ; and

R^{22} is a member selected from the group consisting of C_{1-8} alkyl, aryl, and heteroaryl, which alkyl, aryl, and heteroaryl are optionally substituted with 1 to 3 substituents independently selected from halo, alkyl, mono- or dialkylamino, alkyl or aryl or heteroaryl amide, CN , $O-C_{1-6}$ alkyl, CF_3 , aryl, and heteroaryl.

54. (New) The ~~2,6,9~~-trisubstituted purine composition of claim 50 wherein X=NH.

55. (New) The ~~2,6,9~~-trisubstituted purine composition of claim 52 wherein R₁' is selected from the group consisting of aralkyl and heteroarylalkyl.

56. (New) The ~~2,6,9~~-trisubstituted purine composition of claim 55 wherein R₁' is selected from the group consisting of aralkyl, unsubstituted pyridylalkyl and substituted pyridylalkyl and wherein R₂ is selected from the group consisting of lower alkyl, substituted lower alkyl, and alkyl cycloalkyl.

57. (New) A ~~2,6,9~~-trisubstituted purine composition of claim 54 wherein:
R₁ is an aryl, heteroaryl, heterocyclyl, aralkyl, heteroarylalkyl, each having one to 20 carbon atoms, which aryl, heteroaryl, heterocyclyl, aralkyl, heteroarylalkyl, are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, CF₃, aryl, R²², SR²⁰, S(O)R²¹, SO₂R²¹, SO₂NR²⁰R²³, NR²⁰R²³, NR²⁰COR²¹, NR²⁰CO₂R²¹, NR²⁰SO₂R²¹, OR²⁰, CN, CO₂R²⁰, and CONR²⁰R²³;

R₂ is a hydrogen or hydrocarbon selected from the group substituted lower alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl each having one to 10 carbon atoms wherein substitution includes optional substitution with from 1 to 2 substituents independently selected from the group consisting of halo, R²², SR²⁰, S(O)R²¹, SO₂R²¹, NR²⁰R²³, OR²⁰, and CN;

R₄ and R₅ are each independently hydrogen, or a hydrocarbon selected from the group including alkyl, acyl, heterocyclyl, aryl, heteroaryl, aralkyl, alkenyl, and alkynyl, each having one to 20 carbon atoms, which alkyl, acyl, heterocyclyl, aryl, heteroaryl, aralkyl, alkenyl, and alkynyl, are optionally substituted with from 1 to 2 substituents

independently selected from the group consisting of halo, aryl, R^{22} , SR^{20} , $NR^{20}R^{23}$, $NR^{20}COR^{21}$, $NR^{20}CO_2R^{21}$, $NR^{20}SO_2R^{21}$, OR^{20} , CN, CO_2R^{20} , and $CONR^{20}R^{23}$ with the proviso that either R_4 or R_5 must be substituted with $NR_{20}R_{23}$;

R^{20} is a member selected from the group consisting of H, C_{1-8} alkyl, which alkyl is optionally substituted with 1 to 2 substituents independently selected from halo, alkyl, mono- or dialkylamino, alkyl or CN, $O-C_{1-6}$ alkyl, CF_3 ;

R^{21} is a member selected from the group consisting of C_{1-8} alkyl, which alkyl is optionally substituted with 1 to 2 substituents independently selected from the group of halo, CF_3 , CN, OR^{20} , SR^{20} , $N(R^{20})_2$; and

R^{22} is a member selected from the group consisting of C_{1-3} alkyl, aryl, heteroaryl which alkyl, aryl, and heteroaryl are optionally substituted with 1 to 3 substituents independently selected from halo, alkyl, mono- or dialkylamino, alkyl or aryl, CN, $O-C_{1-6}$ alkyl, CF_3 .

58. (New) The 2,6,9-trisubstituted purine composition of claim 52 wherein R_1' is selected from the group consisting of aryl, heterocyclyl, heteroaryl, substituted heteroaryl, and substituted aryl.

59. (New) The 2,6,9-trisubstituted purine composition of claim 52 wherein R_1' is selected from the group consisting of aryl, unsubstituted pyridyl, substituted pyridyl, and substituted aryl, and R_2 is selected from the group consisting of alkyl, substituted alkyl.

60. (New) The 2,6,9-trisubstituted purine composition of claim 51 wherein R_4 and R_5 are each selected from the group consisting of hydrogen, alkyl, heterocyclyl, acyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkyl alkenyl, alkyl alkynyl, each having one to 20 carbon atoms, which alkyl, acyl, heterocyclyl, aryl, heteroaryl, aralkyl,

B⁶
cont

heteroarylalkyl, are optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, aryl, heteroaryl, heterocyclyl, R^{22} , SR^{20} , $S(O)R^{21}$, SO_2R^{21} , $SO_2NR^{20}R^{23}$, $NR^{20}R^{23}$, $NR^{20}COR^{21}$, $NR^{20}CO_2R^{21}$, $NR^{20}CONR^{20}R^{23}$, $NR^{20}SO_2R^{21}$, OR^{20} , CN, CO_2R^{20} , $CONR^{20}R^{23}$, and COR^{20} with the proviso that either R_4 or R_5 must be substituted with $NR_{20}R_{23}$.

61. (New) A 2,6,9-trisubstituted purine composition of claim 60 wherein:

A1

R'_1 is an aryl, substituted aryl, each having 6 carbon atoms wherein substitution includes optional substitution with from 1 to 2 substituents independently selected from the group consisting of halo, CF_3 , aryl, R^{22} , $NR^{20}R^{23}$, $NR^{20}COR^{21}$, OR^{20} , CN;

R_2 is a hydrogen or hydrocarbon selected from the group substituted lower alkyl, cycloalkyl, substituted cycloalkyl each having one to 6 carbon atoms wherein substitution includes optional substitution with from 1 to 2 substituents independently selected from the group consisting of halo, R^{22} , $NR^{20}R^{23}$, OR^{20} ;

R_4 and R_5 are each independently hydrogen, or a hydrocarbon selected from the group including alkyl, and heterocyclyl wherein each hydrocarbon has from 1 to 12 carbon atoms; which alkyl, and heterocyclyl are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, R^{22} , SR^{20} , OR^{20} , $NR^{20}R^{23}$, CN, CO_2R^{20} , and $CONR^{20}R^{23}$ with the proviso that either R_4 or R_5 must be substituted with $NR_{20}R_{23}$;

R^{20} is a member selected from the group consisting of H, C_{1-8} alkyl;

R^{21} is a member selected from the group consisting of C_{1-3} alkyl, which alkyl is optionally substituted with 1 to 2 substituents independently selected from the group of halo, CF_3 , CN, OR^{20} , SR^{20} , $N(R^{20})_2$; and

B6
cont

R^{22} is a member selected from the group consisting of C_{1-3} alkyl, aryl, heteroaryl which alkyl, aryl, and heteroaryl are optionally substituted with 1 to 3 substituents independently selected from halo, alkyl, mono- or dialkylamino, alkyl or aryl, CN, $O-C_{1-6}$ alkyl, CF_3 .

62. (New) A 2,6,9-trisubstituted purine composition of claim 60 wherein:

A1
Sub
B7

R'_1 is an aryl, substituted aryl, each having 6 carbon atoms wherein substitution includes optional substitution with from 1 to 2 substituents independently selected from the group consisting of halo, CF_3 , R^{22} , OR^{20} , CN;

R_2 is isopropyl

R_4 and R_5 are each independently hydrogen, or a hydrocarbon selected from the group including alkyl, and heterocyclyl wherein each hydrocarbon has from 1 to 12 carbon atoms, which alkyl, and heterocyclyl are optionally substituted with from 1 substituent independently selected from the group consisting of R^{22} , OR^{20} , $NR^{20}R^{23}$ with the proviso that either R_4 or R_5 must be substituted with $NR_{20}R_{23}$;

R^{20} is a member selected from the group consisting of H, C_{1-2} alkyl;

R^{21} is a member selected from the group consisting of C_{1-3} alkyl;

R^{22} is a member selected from the group consisting of C_{1-3} alkyl, aryl, which alkyl, aryl, are optionally substituted with 1 substituent independently selected from halo, alkyl, mono- or dialkylamino, CN, CF_3 ; and

R^{23} is R^{21} or H.

63. (New) A 2,6,9-trisubstituted purine composition of claim 60 wherein:

R'_1 is an aralkyl, substituted aralkyl, each having 6-8 carbon atoms wherein substitution includes optional substitution with from 1 to 2 substituents independently

selected from the group consisting of halo, CF_3 , aryl, R^{22} , $\text{NR}^{20}\text{R}^{23}$, $\text{NR}^{20}\text{COR}^{21}$, OR^{20} , CN;

Sub B7
 R_2 is a hydrogen or hydrocarbon selected from the group substituted alkyl, cycloalkyl, substituted cycloalkyl each having one to 6 carbon atoms wherein substitution includes optional substitution with from 1 substituent independently selected from the group consisting of halo, R^{22} , $\text{NR}^{20}\text{R}^{23}$, OR^{20} ;

AX
 R_4 and R_5 are each independently hydrogen, or a hydrocarbon selected from the group including alkyl and heterocyclyl wherein each hydrocarbon has from 1 to 12 carbon atoms, which alkyl and heterocyclyl are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, R^{22} , SR^{20} , OR^{20} , $\text{NR}^{20}\text{R}^{23}$, CN, CO_2R^{20} , and $\text{CONR}^{20}\text{R}^2$ with the proviso that either R_4 or R_5 must be substituted with $\text{NR}_{20}\text{R}_{23}$;

R^{20} is a member selected from the group consisting of H, C_{1-8} alkyl;

R^{21} is a member selected from the group consisting of C_{1-3} alkyl, which alkyl is optionally substituted with 1 to 2 substituents independently selected from the group of halo, CF_3 , CN, OR^{20} , SR^{20} , $\text{N}(\text{R}^{20})_2$; and

R^{22} is a member selected from the group consisting of C_{1-3} alkyl, aryl, heteroaryl which alkyl, aryl, and heteroaryl are optionally substituted with 1 to 3 substituents independently selected from halo, alkyl, mono- or dialkylamino, alkyl or aryl, CN, O-C_{1-6} alkyl, CF_3 .

64. (New) A 2,6,9-trisubstituted purine composition of claim 60 wherein:

Sub
B7
A1
R¹ is -CH₂-phenyl wherein the phenyl ring is optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, CF₃, R²², OR²⁰, CN;

R₂ is isopropyl;

R₄ and R₅ are each independently hydrogen, or a hydrocarbon selected from the group including alkyl, and heterocyclyl wherein each hydrocarbon has from 1 to 12 carbon atoms, which alkyl, and heterocyclyl are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of R²², OR²⁰, NR²⁰R²³ with the proviso that either R₄ or R₅ must be substituted with NR₂₀R₂₃;

R²⁰ is a member selected from the group consisting of H, C₁₋₂alkyl;

R²¹ is a member selected from the group consisting of C₁₋₃ alkyl;

R²² is a member selected from the group consisting of C₁₋₃alkyl, aryl, which alkyl, aryl, are optionally substituted with 1 substituent independently selected from halo, alkyl, mono- or dialkylamino, CN, CF₃; and

R²³ is R²¹ or H.

65. (New) The 2,6,9-trisubstituted purine composition of claim 60 wherein R₁' is selected from the group consisting of aralkyl, substituted pyridylalkyl, and unsubstituted pyridylalkyl;

R₂ is selected from the group consisting of alkyl, which alkyl is optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, R²², NR²⁰R²³, OR²⁰;

506
B7
AT

R_4 is a substituted alkyl having from 2 to 6 carbon atoms optionally substituted with from 1 to 3 substituents independently selected from the group consisting of R^{22} , OR^{20} , $NR^{20}R^{23}$;

R_5 is selected from the group consisting of hydrogen, alkyl, acyl, heterocyclyl, aryl, heteroaryl, aralkyl, each having one to 20 carbon atoms, which alkyl, acyl, heterocyclyl, aryl, heteroaryl, aralkyl, are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, aryl, R^{22} , SR^{20} , $NR^{20}R^{23}$, $NR^{20}COR^{21}$, $NR^{20}CO_2R^{21}$, $NR^{20}SO_2R^{21}$, OR^{20} , CN , CO_2R^{20} , and $CONR^{20}R^{23}$ with the proviso that either R_4 or R_5 must be substituted with $NR^{20}R^{23}$;

R^{20} is a member selected from the group consisting of H, C_{1-2} alkyl;

R^{21} is a member selected from the group consisting of C_{1-3} alkyl;

R^{22} is a member selected from the group consisting of C_{1-3} alkyl, aryl, which alkyl, aryl, are optionally substituted with 1 substituent independently selected from halo, alkyl, mono- or dialkylamino, CN , CF_3 ; and

R^{23} is R^{21} or H;

66. (New) The 2,6,9-trisubstituted purine composition of claim 60 wherein R_1 is selected from the group consisting of aryl, substituted aryl, pyridyl, and substituted pyridyl;

R_2 is selected from the group consisting of alkyl, which alkyl is optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, R^{22} , $NR^{20}R^{23}$, OR^{20} ;

~~R₄ is a substituted alkyl having from 2 to 6 carbon atoms optionally substituted with from 1 to 3 substituents independently selected from the group consisting of R²², OR²⁰, NR²⁰R²³;~~

~~R₅ is selected from the group consisting of hydrogen, alkyl, acyl, heterocyclyl, aryl, heteroaryl, aralkyl, each having one to 20 carbon atoms, which alkyl, acyl, heterocyclyl, aryl, heteroaryl, aralkyl, are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, aryl, R²², SR²⁰, NR²⁰R²³, NR²⁰COR²¹, NR²⁰CO₂R²¹, NR²⁰SO₂R²¹, OR²⁰, CN, CO₂R²⁰, and CONR²⁰R²³ with the proviso that either R₄ or R₅ must be substituted with NR₂₀R₂₃;~~

~~R²⁰ is a member selected from the group consisting of H, C₁₋₂ alkyl;~~

~~R²¹ is a member selected from the group consisting of C₁₋₃ alkyl;~~

~~R²² is a member selected from the group consisting of C₁₋₃ alkyl, aryl, which alkyl, aryl, are optionally substituted with 1 substituent independently selected from halo, alkyl, mono- or dialkylamino, CN, CF₃; and~~

~~R²³ is R²¹ or H.~~

~~67. (New) The 2,6,9-trisubstituted purine composition of claim 60 wherein R₁' is selected from the group consisting of aralkyl, pyridylalkyl, and substituted pyridylalkyl;~~

~~R₂ is selected from the group consisting of alkyl, which alkyl is optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, R²², and OR²⁰;~~

~~R₄ and R₅ are each alkyl having from 2 to 6 carbon atoms substituted with 1 substituent independently selected from the group consisting of R²²,~~

Sub
B9
A1
NR²⁰R²³, and OR²⁰ with the proviso that either R₄ or R₅ must be substituted with NR₂₀R₂₃;

R²⁰ is a member selected from the group consisting of H, C₁₋₂ alkyl;

R²¹ is a member selected from the group consisting of C₁₋₃ alkyl;

R²² is a member selected from the group consisting of C₁₋₃ alkyl; and

R²³ is R²¹ or H.

68. (New) The 2,6,9-trisubstituted purine composition of claim 60 wherein R₁' is CH₂-Aryl or CH₂-substituted aryl, R₂ is lower alkyl, and R₄ = H, and R₅ is -CH₂CH₂NH₂, CHR'CH₂NH₂, -CH₂CHR'NH₂ wherein R' is hydrogen or alkyl having from 1 to 6 carbon atoms.

69. (New) The 2,6,9-trisubstituted purine composition of claim 68 wherein R₂ is isopropyl.

70. (New) The 2,6,9-trisubstituted purine composition of claim 60 wherein R₁' is CH₂-Aryl or CH₂-substituted aryl, R₂ is lower alkyl, and R₄ = -CH₂CH₂OH R₅ is CH₂CH₂NH₂, or -CHR'CH₂NH₂, or -CH₂CHR'NH₂ wherein R' is hydrogen or alkyl having from 1 to 6 carbon atoms.

71. (New) The 2,6,9-trisubstituted purine composition of claim 70 wherein R₂ is isopropyl.

72. (New) The 2,6,9-trisubstituted purine composition of claim 60 wherein R₁' is selected from the group consisting of aryl, substituted aryl, pyridyl, and substituted pyridyl, R₂ is selected from the group consisting of lower alkyl, substituted lower alkyl, and alkyl cycloalkyl, and R₄ and R₅ are each a substituted lower alkyl having from 2 to 6 carbon atoms.

73. (New) The 2,6,9-trisubstituted purine composition of claim 60 wherein R_1' is benzyl substituted with a halogen, alkoxy, phenyl, pyridyl or nitro group, R_2 is isopropyl, $R_4 = H$, and $R_5 = CH_2CH_2NH_2$.

74. (New) The 2,6,9-trisubstituted purine composition of claim 60 wherein R_1' is benzyl substituted with a halogen, alkoxy, C_{1-3} alkyl, CF_3 , phenyl, pyridyl or nitro group, R_2 is isopropyl, $R_4 = H$, and $R_5 = CH_2CHR'NH_2$ wherein R' is hydrogen or alkyl having from 1 to 6 carbon atoms.

75. (New) The 2,6,9-trisubstituted purine composition of claim 60 wherein R_1' is benzyl substituted with a halogen, alkoxy, C_{1-3} alkyl, CF_3 , phenyl, pyridyl or nitro group, R_2 is isopropyl, $R_4 = H$, and $R_5 = CH_2CR'R'NH_2$ wherein R' is hydrogen or alkyl having from 1 to 6 carbon atoms.

76. (New) The 2,6,9-trisubstituted purine composition of claim 50 selected from the group consisting of 2-((2-hydroxyethyl)[9-(methylethyl)-6-({[4-(trifluoromethyl)phenyl]methyl}amino)purin-2-yl]amino)ethan-1-ol, (((2S)oxolan-2-yl)methyl)(6-({[4-fluorophenyl]methyl}amino)-9-(methylethyl)purin-2-yl)amine, [((2R)oxolan-2-yl)methyl](6-({[4-fluorophenyl]methyl}amino)-9-(methylethyl)purin-2-yl)amine, (2-aminoethyl)(6-({[3,5-dichlorophenyl]methyl}amino)-9-(methylethyl)purin-2-yl)amine, (2-aminoethyl)[6-({[4-chloro-3-(trifluoromethyl)phenyl]methyl}amino)-9-(methylethyl)purin-2-yl]amine, [-(6-({[4-chlorophenyl]methyl}amino)-9-(methylethyl)purin-2-yl)amino]-3-methylbutanamide, (2-amino-2-methylpropyl)(6-({[4-chlorophenyl]methyl}amino)-9-(methylethyl)purin-2-yl)amine, 3-(2-[bis(2-hydroxyethyl)amino]-6-({[4-chlorophenyl]methyl}amino)purin-9-yl)butan-2-one,

2-[(6-[[[(4-chlorophenyl)methyl]amino]-9-(methylethyl)purin-2-yl]amino]-3-methylbutan-1-ol, 4-[(2-[(2-aminoethyl)amino]-9-(methylethyl)purin-6-yl]amino)methyl]benzenesulfonamide, 2-[(2-hydroxyethyl)(6-[[[(4-methoxyphenyl)methyl]amino]-9-(methylethyl)purin-2-yl]amino]ethan-1-ol, 2-[(2-hydroxyethyl)(9-(methylethyl)-6-[(4-phenylphenyl)amino]purin-2-yl]amino)ethan-1-ol, {2-[(2-amino-2-propyl)amino]-9-(methylethyl)purin-6-yl}[(4-chlorophenyl)methyl]amine, {2-[(2-aminoethyl)amino]-9-(methylethyl)purin-6-yl}[(4-chlorophenyl)methyl]amine, {2-[(2-aminopropyl)amino]-9-(methylethyl)purin-6-yl}[(4-chlorophenyl)methyl]amine and 2-[(2-aminoethyl)(6-[[[(4-chlorophenyl)methyl]amino]-9-(methylethyl)purin-2-yl]amino]ethan-1-ol.

77. (New) The 2,6,9-trisubstituted purine composition of claim 60 wherein R₁' is selected from the group consisting of 3-methylthiophenyl, 4-methylthiophenyl, 4-phenylbenzyl, 4-methoxybenzyl, 4-biphenyl, 3-methoxybenzyl, 4-(2-thienyl)benzyl, 4-(4-methyl)phenylbenzyl, 4-(4-trifluoromethyl)phenylbenzyl, 4-(4-nitrilo)phenylbenzyl, 4-(2-pyridinyl)benzyl, piperonyl, 3-methoxybenzyl, 4-chlorobenzyl, and 4-nitrobenzyl, and R₂ is isopropyl.

78. (New) The 2,6,9-trisubstituted purine composition of claim 77 wherein R₁' is selected from the group of compounds consisting of 4-methoxybenzyl, 4-phenylbenzyl, 4-methoxybenzyl, 4-biphenyl, 3-methoxybenzyl, 4-(2-thienyl)benzyl, 4-(4-methyl)phenylbenzyl, 4-(4-trifluoromethyl)phenylbenzyl, 4-(4-nitrilo)phenylbenzyl, 4-(2-pyridinyl)benzyl, piperonyl, 3-thiomethoxyphenyl, 4-thiomethoxyphenyl and 4-bromophenyl.

79. (New) A cationic salt of the composition of claim 50.

80. (New) An acid addition salt of the composition of claim 50.

81. A method for inhibiting cell proliferation in mammals comprising administering a therapeutically effective amount of the composition of claim 50 to the mammal.

82. (New) The method of claim 81 wherein the therapeutically effective amount ranges from about 0.001 to about 100 mg/kg weight of the mammal.

83. (New) The method of claim 81 wherein the composition is administered to a mammal suffering from a cell proliferation disorder selected from the group consisting of rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, cancer, restenosis following ballon angioplasty or atherectomy, restenosis following vascular modifying surgical procedures, host graft disease, and gout.

84. (New) The method of claim 83 wherein the cell proliferation disorder is restenosis.

85. (New) The method of claim 83 wherein the cell proliferation is disorder cancer.

86. (New) The method of claim 83 wherein the cell proliferation disorder is polycystic kidney disease.

87. (New) The method of claim 83 wherein the mammal is a human.

88. (New) A pharmaceutical composition of matter comprising the composition of claim 50 and one or more pharmaceutical excipients.

89. (New) An antifungal agent useful for treating fungal infections in humans, and animals comprising the composition of claim 50.

90. (New) The method of claim 42 wherein the cell proliferation disorder is selected from the group consisting of lymphoid neoplasm, cancer of the colon, breast